Pharmacokinetics and Food Effect of Sarpogrelate HCl CR Formulation in Comparison to Immediate-release Formulation
NCT ID: NCT01841086
Last Updated: 2013-04-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
50 participants
INTERVENTIONAL
2011-09-30
2011-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Sarpogrelate Drug Interaction
NCT02097511
COREG MR Versus TOPROL-XL On The Lipid Profile Of Normolipidemic Or Mildly Dyslipidemic Patients With Hypertension
NCT00273052
Irbesartan/Hydrochlorothiazide to Control Elevated Blood Pressure to Target in Moderate to Severe Hypertensive Patients
NCT00670566
A Study to Evaluate Efficacy and Safety of HGP2102 in Essential Hypertension Patients
NCT06174766
Phase IIa Safety and Efficacy Study of SPP635 in Mild to Moderate Hypertension
NCT00376636
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Anplag
Sarpogrelate HCl 300mg once a day or 100mg three times a day
Anplag
Sarpogrelate HCl 300mg once a day or 100mg three times a day
UI03SPG300CT
Sarpogrelate HCl 300mg once a day or 100mg three times a day
UI03SPG300CT
Sarpogrelate HCl 300mg once a day or 100mg three times a day
Anplag
Sarpogrelate HCl 300mg once a day or 100mg three times a day
UI03SPG300CT
Sarpogrelate HCl 300mg once a day or 100mg three times a day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Anplag
Sarpogrelate HCl 300mg once a day or 100mg three times a day
UI03SPG300CT
Sarpogrelate HCl 300mg once a day or 100mg three times a day
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
20 Years
55 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Korea United Pharm. Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Wooseong Huh, M.D., Ph.D.
Role: PRINCIPAL_INVESTIGATOR
Samsung Medical Center
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KUP-SPG3-101
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.